MX2020008894A - Inhibidores de oxazin monoacilglicerol lipasa (magl). - Google Patents

Inhibidores de oxazin monoacilglicerol lipasa (magl).

Info

Publication number
MX2020008894A
MX2020008894A MX2020008894A MX2020008894A MX2020008894A MX 2020008894 A MX2020008894 A MX 2020008894A MX 2020008894 A MX2020008894 A MX 2020008894A MX 2020008894 A MX2020008894 A MX 2020008894A MX 2020008894 A MX2020008894 A MX 2020008894A
Authority
MX
Mexico
Prior art keywords
magl
oxazine
inhibitors
monoacylglycerol lipase
sup
Prior art date
Application number
MX2020008894A
Other languages
English (en)
Inventor
Luca Gobbi
Uwe Grether
Benoit Hornsperger
Bernd Kuhn
Zbinden Katrin Groebke
Hans Richter
Joerg Benz
Buelent Kocer
Rui Chen
Carsten Kroll
Satoshi Tsuchiya
Charles Bell
Dennis Jul Hansen
Fionn O`Hara
Martin Ritter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020008894A publication Critical patent/MX2020008894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (Ic), en la que A, L, X, m, n y R20 a R23 son tal como se describe en el presente documento, composiciones que incluyen los compuestos, procesos de preparación de los compuestos y métodos de uso de los compuestos.
MX2020008894A 2018-03-22 2019-03-22 Inhibidores de oxazin monoacilglicerol lipasa (magl). MX2020008894A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18163273 2018-03-22
CN2019075372 2019-02-18
PCT/EP2019/057174 WO2019180185A1 (en) 2018-03-22 2019-03-22 Oxazine monoacylglycerol lipase (magl) inhibitors

Publications (1)

Publication Number Publication Date
MX2020008894A true MX2020008894A (es) 2020-10-12

Family

ID=65818027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008894A MX2020008894A (es) 2018-03-22 2019-03-22 Inhibidores de oxazin monoacilglicerol lipasa (magl).

Country Status (27)

Country Link
US (2) US20210107920A1 (es)
EP (1) EP3768684B1 (es)
JP (1) JP7308220B2 (es)
KR (1) KR20200136425A (es)
CN (1) CN111936503B (es)
AU (1) AU2019238381B2 (es)
BR (1) BR112020014992A2 (es)
CA (1) CA3089443A1 (es)
CL (1) CL2020002423A1 (es)
CO (1) CO2020009567A2 (es)
CR (1) CR20200416A (es)
DK (1) DK3768684T3 (es)
ES (1) ES2942319T3 (es)
FI (1) FI3768684T3 (es)
HR (1) HRP20230388T1 (es)
HU (1) HUE061584T2 (es)
IL (1) IL276031B2 (es)
LT (1) LT3768684T (es)
MX (1) MX2020008894A (es)
PE (1) PE20201185A1 (es)
PH (1) PH12020500661A1 (es)
PL (1) PL3768684T3 (es)
RS (1) RS64156B1 (es)
SG (1) SG11202007608UA (es)
SI (1) SI3768684T1 (es)
TW (1) TWI818967B (es)
WO (1) WO2019180185A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
KR20220062515A (ko) * 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
CN114401969A (zh) * 2019-09-23 2022-04-26 豪夫迈·罗氏有限公司 杂环化合物
JP2022549306A (ja) * 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ
KR20220069003A (ko) * 2019-09-24 2022-05-26 에프. 호프만-라 로슈 아게 헤테로사이클릭 모노아실글리세롤 리파제(magl) 억제제
CA3155724A1 (en) * 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds
CA3234429A1 (en) * 2021-10-15 2023-04-20 Luc Farmer Ras inhibitors, compositions and methods of use thereof
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
WO2024061853A1 (en) * 2022-09-20 2024-03-28 F. Hoffmann-La Roche Ag Fluorescent probes for magl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
MX2007016523A (es) 2005-06-20 2008-03-06 Schering Corp Piperidinas sustituidas ligadas a carbono y derivados de las mismas utiles como antagonistas de hsitamina h3.
AU2007217040A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
US7872028B2 (en) 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
EP2709985B1 (en) 2011-05-16 2017-10-04 Bionomics Limited Amine derivatives as potassium channel blockers
HUE049690T2 (hu) * 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
AU2016261031A1 (en) 2015-05-13 2017-10-05 Selvita S.A. Substituted quinoxaline derivatives
WO2016185279A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN105198903B (zh) * 2015-11-09 2016-08-24 代先慧 一种治疗急性上呼吸道感染的药物组合物
WO2017170830A1 (ja) * 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
RU2020133991A (ru) 2022-04-22
FI3768684T3 (fi) 2023-04-26
DK3768684T3 (da) 2023-04-24
CN111936503A (zh) 2020-11-13
HUE061584T2 (hu) 2023-07-28
HRP20230388T1 (hr) 2023-06-23
CL2020002423A1 (es) 2021-02-19
LT3768684T (lt) 2023-04-25
EP3768684A1 (en) 2021-01-27
US20230117324A1 (en) 2023-04-20
WO2019180185A8 (en) 2020-10-22
EP3768684B1 (en) 2023-02-22
ES2942319T3 (es) 2023-05-31
JP7308220B2 (ja) 2023-07-13
JP2021517575A (ja) 2021-07-26
SG11202007608UA (en) 2020-09-29
PH12020500661A1 (en) 2021-06-28
BR112020014992A2 (pt) 2020-12-29
WO2019180185A1 (en) 2019-09-26
US20210107920A1 (en) 2021-04-15
RS64156B1 (sr) 2023-05-31
CA3089443A1 (en) 2019-09-26
TWI818967B (zh) 2023-10-21
SI3768684T1 (sl) 2023-06-30
PL3768684T3 (pl) 2023-07-10
KR20200136425A (ko) 2020-12-07
CR20200416A (es) 2020-10-26
IL276031A (en) 2020-08-31
CO2020009567A2 (es) 2020-08-10
AU2019238381A1 (en) 2020-08-06
PE20201185A1 (es) 2020-11-03
AU2019238381B2 (en) 2022-07-07
CN111936503B (zh) 2023-09-12
IL276031B2 (en) 2023-06-01
TW202003525A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2020008894A (es) Inhibidores de oxazin monoacilglicerol lipasa (magl).
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
MX2021005714A (es) Nuevos compuestos heterociclicos.
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2022002311A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
CR20220116A (es) Compuestos heterocíclicos
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20220004A (es) Nuevos compuestos heterocíclicos
CR20220117A (es) Compuestos heterocíclicos
MX2023002224A (es) Compuestos heterociclicos.
MX2023012477A (es) Compuestos heterociclicos.
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
MX2021002087A (es) Derivados de heteroarilo biciclicos.